74 results
8-K
NKTX
Nkarta Inc
27 Jun 24
Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis
6:45am
, accessibility, tolerability, advantages, and safety profile of NK cell therapies, including NKX019, for the treatment of autoimmune disease, including lupus
8-K
EX-99.1
NKTX
Nkarta Inc
27 Jun 24
Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis
6:45am
nephritis and the IND clearance for three additional indications are critical milestones in our mission to improve the accessibility and safety of cell … therapy. NKX019 is unencumbered by many of the safety, infrastructure and logistical challenges associated with existing cell therapy approaches
8-K
EX-99.1
NKTX
Nkarta Inc
13 Jun 24
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors
4:22pm
that transform patient care. NK cell therapy has breakthrough potential to treat debilitating autoimmune diseases without the safety concerns … potential, accessibility, tolerability, advantages, and safety profile
of NK cell therapies, including NKX019 for the treatment of autoimmune diseases
8-K
EX-99.1
NKTX
Nkarta Inc
9 May 24
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
4:04pm
like NKX019 could address the infrastructure and safety concerns that have created barriers to patient access across our industry. We are excited … clinical trial will assess the safety and clinical activity of NKX019 in patients with refractory lupus nephritis (LN). Per the protocol, patients
8-K
EX-1.1
jd3bk1eea46
28 Mar 24
Other Events
4:08pm
424B5
eqcy4sjqicli
25 Mar 24
Prospectus supplement for primary offering
8:15pm
8-K
5xrhaz
25 Mar 24
Regulation FD Disclosure
6:05am
8-K
EX-99.1
qs39p6
25 Mar 24
Regulation FD Disclosure
6:05am
8-K
EX-99.1
lglzydz5 ahthmn40wc
21 Mar 24
Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
4:15pm
8-K
EX-99.1
1chnged0wk fppg
8 Jan 24
Regulation FD Disclosure
8:50am
8-K
EX-99.1
grs h7mtvymg
9 Nov 23
Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights
4:06pm
8-K
EX-99.1
h7mdgj
17 Oct 23
Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis
7:06am
8-K
nk156kz
17 Oct 23
Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis
7:06am
8-K
EX-99.1
sj3ri
10 Aug 23
Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights
7:05am
8-K
EX-99.1
kpnrstjl iy9p72v
27 Jun 23
Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia
7:07am
8-K
EX-99.2
uykkd4nkfwockwq4ij5
27 Jun 23
Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia
7:07am